Welcome to our dedicated page for Parkervision SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for ParkerVision, Inc. (PRKR), a Florida corporation focused on radio-frequency (RF) technologies for advanced wireless communication systems. Through its periodic and current reports, ParkerVision provides detailed information on its operations, financial condition, litigation posture, and capital-raising activities.
Investors can use ParkerVision’s annual reports on Form 10-K and quarterly reports on Form 10-Q to review its RF technology and licensing focus, operating expenses, net losses, contingent payment obligations, and cash flows. These filings also include risk factor discussions that the company references in its press releases, covering topics such as outcomes of patent litigation, interpretations of patent law and claim scope, decisions by the Patent Trial and Appeal Board (PTAB), and market conditions affecting financing.
Current reports on Form 8-K are particularly important for tracking material events. Recent 8-K filings describe registered direct offerings of common stock under ParkerVision’s effective shelf registration statement on Form S-3, including sales to accredited investors and to a director. These filings outline subscription agreements, offering prices, aggregate purchase amounts, and legal opinions regarding the issuance of securities. Other 8-Ks furnish earnings press releases that summarize quarterly and year-to-date financial results and provide context for changes in operating expenses and contingent payment obligations.
Through this filings page, users can access ParkerVision’s real-time updates as they are filed with EDGAR, including 10-K, 10-Q, and 8-K reports, as well as registration statements and prospectus supplements related to its shelf registration. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections such as litigation disclosures, capital structure changes, and risk factors, and make it easier to interpret complex legal and financial language without replacing the full primary documents.
ParkerVision, Inc. updated its April 2020 resale prospectus to cover up to 16,809,295 shares of common stock that may be sold from time to time by existing stockholders. These shares include stock already issued, shares issuable from convertible notes, and up to 5,200,000 shares underlying warrants held by Aspire Capital and Tailwinds. The company will not receive proceeds from stockholder resales, but could receive up to $3,900,000 if the Aspire and Tailwinds warrants are exercised for cash.
Separately, ParkerVision completed a registered offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its shelf registration statement. The company did not use underwriters or pay commissions in this transaction, and disclosed the closing and related agreements through its Form 8-K and attached exhibits.
ParkerVision, Inc. has an effective prospectus supplement that permits the resale by existing stockholders of up to 18,014,164 shares of common stock. These consist of up to 5,457,583 shares issuable under Tranche 1 convertible notes at a fixed conversion price of $0.10 per share, up to 10,131,581 shares issuable under Tranche 2 convertible notes at a fixed conversion price of $0.08 per share, 625,000 shares issued for services under the Fisher Consulting Agreement, and up to 1,800,000 shares issuable upon exercise of the Park Consulting Warrant with a $0.10 exercise price.
The company will not receive proceeds from resale of these shares by selling stockholders, but could receive up to $180,000 in gross proceeds if the Park Consulting Warrant is exercised for cash. Separately, ParkerVision completed a registered offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132 under its Form S-3 shelf registration statement, with no commissions or fees paid.
ParkerVision, Inc. has filed a prospectus supplement covering the resale by existing stockholders of up to 17,189,660 shares of common stock. These shares include stock and warrants from a 2016 private placement, shares issued and issuable under a 2018 PIPE agreement with Aspire Capital, and shares issuable upon conversion of 2018 convertible notes. The company will not receive proceeds from stockholder resales, but could receive up to $700,000 from cash exercises of a 2016 warrant and up to $1,763,500 from sales of common stock or warrant exercises under the Aspire Capital agreement.
Separately, ParkerVision completed a registered direct offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its Form S-3 shelf registration. No underwriters, placement agents, brokers, or finders were involved and no commissions or fees were paid.
ParkerVision, Inc. has filed a prospectus supplement that continues to permit the resale by selling stockholders of up to 12,800,000 shares of common stock previously registered under its shelf program. These shares consist of up to 7,800,000 shares issuable upon conversion of, or payment of interest on, convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant.
The company will not receive proceeds from resale of these shares, but could receive up to $800,000 in gross proceeds if the warrant is exercised for cash, which it expects to use for patent enforcement, working capital, and general corporate purposes. The attached Form 8-K discloses that ParkerVision also completed a separate registered offering of 16,481,579 common shares to accredited investors for an aggregate purchase price of $3,461,132, with no commissions or fees paid.
ParkerVision, Inc. completed a primary offering of 16,481,579 shares of common stock to accredited investors at $0.21 per share, raising gross proceeds of $3,461,132. The shares were sold directly under subscription agreements without underwriters or placement agents, and the deal closed on November 24, 2025.
The company plans to use the cash for working capital, general corporate purposes, and litigation fees and expenses, which align with its IP-enforcement focused business model. On a pro forma basis as of September 30, 2025, cash would increase from $901,000 to $5,470,000, and total shareholders’ deficit would narrow from $(49.8) million to $(45.2) million, though the balance sheet remains highly leveraged.
The offering price creates meaningful dilution. Pro forma as adjusted net tangible book value moves from $(0.39) to $(0.32) per share, implying an immediate dilution of $0.53 per share to new investors buying at $0.21. The company continues to highlight substantial risks, including a limited OTCQB trading market, a need for additional capital, and going concern language in its audited financial statements.
ParkerVision, Inc. (PRKR) reported that on November 24, 2025 it completed an offering and sale of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132. The shares were issued under the company’s existing shelf registration statement on Form S-3 and a prospectus supplement containing the final terms of the offering.
The company conducted this transaction directly, engaging no underwriters, placement agents, brokers, or finders and paying no commissions or fees, so the full purchase price goes to ParkerVision. The company also disclosed that it issued a press release announcing the closing of the transaction, which is included as an exhibit.
ParkerVision, Inc. entered into subscription agreements with accredited investors to sell 16,481,579 shares of common stock at
The shares are being offered under ParkerVision’s existing shelf registration statement on Form S-3, and closing is expected to occur on
ParkerVision director Lewis H. Titterton Jr. filed a Schedule 13D reporting his beneficial ownership in PRKR. As of November 17, 2025, he beneficially owns 8,829,430 shares of common stock, or approximately 6.98% of the 126,311,303 shares outstanding disclosed in a recent prospectus supplement. This total includes 251,260 shares underlying stock options, warrants and restricted stock awards that are exercisable or will vest within 60 days.
Titterton agreed on November 14, 2025 to purchase 4,761,905 shares at $0.21 per share under a Subscription Agreement, with closing on November 17, 2025, and he exercised 800,000 non-qualified stock options at an average exercise price of $0.185 per share. He states he holds the shares for investment purposes and may buy more, hold, sell, or distribute shares over time based on market conditions, the company’s performance, liquidity needs and other factors, subject to company policies including its insider trading policy.
ParkerVision, Inc. (PRKR)4,761,905 shares of common stock at $0.21 per share for an aggregate purchase price of $1,000,000. The price matched the last sale price of ParkerVision common stock on November 14, 2025, and the transaction closed on November 17, 2025. Following this purchase, the director beneficially owns 8,578,170 shares directly. The purchase was executed under an existing shelf registration statement on Form S-3 that was declared effective on May 28, 2025, and was reviewed and approved by the disinterested members of the board in accordance with Florida corporate law.
ParkerVision, Inc. completed a registered direct offering of 4,761,905 shares of common stock to board member Lewis H. Titterton, Jr. for $1,000,000, priced at $0.21 per share, equal to the last reported OTCQB sale price on November 14, 2025. The company received the full amount with no underwriting or placement fees.
Shares outstanding increase from 121,549,398 to 126,311,303, and the transaction causes immediate dilution, with pro forma net tangible book value rising from approximately $(0.42) to $(0.40) per share. Management plans to use the net proceeds for working capital and other general corporate purposes, including litigation fees and expenses, as ParkerVision continues to focus on enforcing its RF patent portfolio.